FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> blockbusters | Amgen | Denosumab

Wall Street swoons over Amgen's D-mab future

Tools

It's been a long time since I've heard the words "love" and "Amgen" in one sentence, but that's the approach the Los Angeles Times took in covering Wall Street's enthusiastic response to D-mab's performance in a recent clinical trial. Oppenheimer's Bret Holley says the drug is on track to break the billion-dollar mark in 2010 with an approval possible in 2009. And that helped send shares of Amgen surging to a 14-month high.

- reaad the story from the Los Angeles Times

Related Articles:
Denosumab--Next gen biotech blockbusters
Amgen shares buoyed by late-stage D-mab data
Amgen's D-mab posts positive in late-stage trial
Amgen's D-mab meets trial goal
Denosumab: Amgen's salvation?

Bookmark and Share
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Denosumab   blockbusters   Amgen  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.